MOBERG DERMA AB ORD news, videos and press releases
For more news please use our advanced search feature.
MOBERG DERMA AB ORD - More news...
MOBERG DERMA AB ORD - More news...
- MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication
- MOB-015 is recommended for approval in EU: Moberg Pharma
- European marketing authorization application for MOB-015 submitted
- The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application
- Moberg Pharma receives approval from the EMA's Paediatric Committee
- Moberg Pharmas Year-end report 2020
- Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea
- New number of shares and votes in Moberg Pharma AB (publ)
- OncoZenge announces issue of European Patent related to BupiZenge®
- OncoZenge raises MSEK 10 ahead of spin-off and separate listing
- Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge
- Invitation to market update in Moberg Pharma on November 25th
- OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing
- Extended fiscal year July 2019 - December 2020 Interim report July - September 2020
- Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million
- Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)
- Moberg Pharma intends to submit a registration application in Europe in 2021
- Moberg Pharma: Interim report April - June 2020
- Appointment of Chief Medical Officer at Moberg Pharma
- New number of Shares and Votes in Moberg Pharma AB (publ)
- Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study
- New Number of Shares and Votes in Moberg Pharma AB (publ)
- Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020
- Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference
- Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)
- Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015
- Moberg Pharma AB Interim Report October - December 2019
- Moberg Pharma's Interim Report to be Published on February 11 - Invitation to Teleconference
- Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015
- Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015
